Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Lunning

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Annals of Hematology|October 20, 2021
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphomaMridula Krishnan, R Gregory Bociek, Michelle Fanale, et al.
Biomaterials|November 2, 2018
Integrated generation of induced pluripotent stem cells in a low-cost deviceHaishuang Lin, Qiang Li, Qian Du, et al.
Leukemia & Lymphoma|August 27, 2020
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center populationPaola Ghione, Shunan Qi, Brandon S Imber, et al.
Leukemia|June 8, 2019
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomasXuan Zhang, Chengfeng Bi, Ting Lu, et al.
Blood|September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaMatthew Lunning, Julie Vose, Loretta Nastoupil, et al.
British Journal of Haematology|December 7, 2018
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphomaJayadev M Umakanthan, Javeed Iqbal, Connie L Batlevi, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Blood Advances|September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCLJeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Blood|October 27, 2023
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Annals of Hematology|October 20, 2021
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphomaMridula Krishnan, R Gregory Bociek, Michelle Fanale, et al.
Biomaterials|November 2, 2018
Integrated generation of induced pluripotent stem cells in a low-cost deviceHaishuang Lin, Qiang Li, Qian Du, et al.
Leukemia & Lymphoma|August 27, 2020
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center populationPaola Ghione, Shunan Qi, Brandon S Imber, et al.
Leukemia|June 8, 2019
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomasXuan Zhang, Chengfeng Bi, Ting Lu, et al.
Blood|September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaMatthew Lunning, Julie Vose, Loretta Nastoupil, et al.
British Journal of Haematology|December 7, 2018
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphomaJayadev M Umakanthan, Javeed Iqbal, Connie L Batlevi, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Blood Advances|September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCLJeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Blood|October 27, 2023
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Pageof 6